Izervay (avacincaptad pegol) is a brand-name eye injection that’s prescribed for an advanced form of age-related macular degeneration. Izervay is not known to interact with other drugs. Izervay is ...
In GATHER2 open-label extension study, IZERVAY reduced GA growth 37-40.5% vs. projected sham, with earlier intervention resulting in greater protection of retinal tissue area Study results found no ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved Izervay to treat geographic atrophy. Izervay demonstrated statistically significant reduction ...
TOKYO, Jan. 8, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) accepted the revised ...
Please provide your email address to receive an email when new articles are posted on . Izervay is now approved without limitation on duration of dosing. The approval is based on data from the phase 3 ...
Over 24 months, dosing with monthly avacincaptad pegol resulted in a statistically significant year-over-year reduction of 14% in the mean rate of GA growth vs sham. The Food and Drug Administration ...
Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic atrophy (GA) med Izervay has taken a few beatings in recent months. Still, the ...
In the face of tough competition from Apellis and a recent setback with prescribers, Astellas’ geographic atrophy (GA) med Izervay has nabbed a much-needed label update from the FDA. The agency lifted ...
*Intended for U.S. Audiences only. Whether it was a weekend getaway to Chicago to see a play or snapping pics of Big Ben in London, going on adventures was always a highlight for Jan,* a 56 year-old ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback